Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission.
about
Evolution of Resistant M414T Mutants among Hepatitis C Virus Replicon Cells Treated with Polymerase Inhibitor A-782759Effectiveness of non-nucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in women previously exposed to a single intrapartum dose of nevirapine: a multi-country, prospective cohort studyEmergence and persistence of minor drug-resistant HIV-1 variants in Ugandan women after nevirapine single-dose prophylaxisRandomized trial of time-limited interruptions of protease inhibitor-based antiretroviral therapy (ART) vs. continuous therapy for HIV-1 infectionEmergence of minor drug-resistant HIV-1 variants after triple antiretroviral prophylaxis for prevention of vertical HIV-1 transmissionThe challenge of HIV-1 antiretroviral resistance in Africa in the era of HAART.Reuse of single-dose nevirapine in subsequent pregnancies for the prevention of mother-to-child HIV transmission in Lusaka, Zambia: a cohort study.Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infantsPersistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy.Sensitive tenofovir resistance screening of HIV-1 from the genital and blood compartments of women with breakthrough infections in the CAPRISA 004 tenofovir gel trialAssociation between detection of HIV-1 DNA resistance mutations by a sensitive assay at initiation of antiretroviral therapy and virologic failure.Detection of HIV-1 drug resistance in women following administration of a single dose of nevirapine: comparison of plasma RNA to cellular DNA by consensus sequencing and by oligonucleotide ligation assay.Ultrasensitive detection of minor drug-resistant variants for HIV after nevirapine exposure using allele-specific PCR: clinical significance.Etravirine (TMC-125): The evidence for its place in the treatment of HIV-1 infectionMinor resistant variants in nevirapine-exposed infants may predict virologic failure on nevirapine-containing ART.Minority variants of drug-resistant HIV.Improvement in allele-specific PCR assay with the use of polymorphism-specific primers for the analysis of minor variant drug resistance in HIV-1 subtype C.Concordance between allele-specific PCR and ultra-deep pyrosequencing for the detection of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.Estimating frequencies of minority nevirapine-resistant strains in chronically HIV-1-infected individuals naive to nevirapine by using stochastic simulations and a mathematical model.Primary drug resistance in South Africa: data from 10 years of surveys.Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutationsAntiretroviral therapies in women after single-dose nevirapine exposure.Induction therapy with protease-inhibitors modifies the effect of nevirapine resistance on virologic response to nevirapine-based HAART in childrenReplicative fitness costs of nonnucleoside reverse transcriptase inhibitor drug resistance mutations on HIV subtype C.Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa.The development of drug resistance mutations K103N Y181C and G190A in long term Nevirapine-containing antiviral therapy.A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.Drug resistance among newly diagnosed HIV-infected children in the era of more efficacious antiretroviral prophylaxis.HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapineOne-Step Ligation on RNA Amplification for the Detection of Point MutationsOptimization of allele-specific PCR using patient-specific HIV consensus sequences for primer designSurveillance of transmitted HIV-1 drug resistance in Gauteng and KwaZulu-Natal Provinces, South Africa, 2005-2009.Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV.Clinical implications of HIV-1 minority variantsTransient antiretroviral therapy selecting for common HIV-1 mutations substantially accelerates the appearance of rare mutations.HIV Drug Resistance Among Children Initiating First-Line Antiretroviral Treatment in UgandaEvolving uses of oral reverse transcriptase inhibitors in the HIV-1 epidemic: from treatment to preventionIdentification of nevirapine-resistant HIV-1 in the latent reservoir after single-dose nevirapine to prevent mother-to-child transmission of HIV-1.Detection and quantification of minor human immunodeficiency virus type 1 variants harboring K103N and Y181C resistance mutations in subtype A and D isolates by allele-specific real-time PCR.Lower risk of resistance after short-course HAART compared with zidovudine/single-dose nevirapine used for prevention of HIV-1 mother-to-child transmission
P2860
Q27480267-3D62526D-18AA-4D39-8562-A96170C6E6A9Q28472889-6DF2BE82-B5B7-4C47-A707-FCED03173931Q28478377-C9FDA74D-3A13-4BAD-8A7A-A15831863BA8Q28478848-C09A3ADA-7EB7-4274-AB43-2155A8698FE3Q28481233-DEFE098C-F6F8-4065-80BA-0E13A6BC76ABQ30425595-132474F8-33D0-4C83-855B-C7EA0099134FQ33396553-A9B5A897-221C-433D-B9EC-AFB880544A90Q33396950-25919FEA-F8C5-438E-A878-CF21C5BCFF4FQ33605273-E58A80BD-6ADB-4DBF-888B-E92AC7A3F64EQ33684387-2D2C870E-6329-463E-890B-ED93DFA098EAQ33798282-CBD49BF3-32B2-47AC-94FE-D0531D344979Q33827080-FD799F18-226B-41E2-88E6-1BCC033AA59AQ33827841-3ABB8F4B-D619-4C75-924E-A0F57511E751Q33973857-E3F1B955-D2DB-4610-9A9F-3D128A339EB5Q34019433-2207BB99-F1A9-434B-B025-DAED0CECD7C1Q34047780-81131272-5D85-42F2-A875-87565F16EEF2Q34081115-6C1788E2-3F43-4B31-9C49-E70DC3362CB0Q34112568-6D7807F8-7957-4BB6-B559-CF4480A1E1F6Q34120725-4F7D333F-1557-409F-A88E-8FEDA1F17885Q34129300-852D7899-1648-47C4-907A-CA59A5EC1979Q34331628-75834B0E-40C2-4B2E-8461-31807C576E30Q34363980-F21A5FF6-F7B4-4D1E-AF11-29F6BF919C92Q34699162-0AB60B60-7749-4A8D-B97B-275A98395BABQ34933329-6D6F95E9-E1D8-4572-B54E-C4A6EEDE4BD7Q35179391-F6A97DF0-1149-47CC-9610-EEFDC1B8D0E0Q35552675-78EC5048-C66C-403F-8BAE-BAF7CB69A993Q35632898-3F15A2B1-B7A1-4677-8550-D7D3ED1743FCQ35965344-85D7D341-DE02-48F4-9BFB-EF0AB544A1C0Q35990257-E3B9ED7A-9E31-4556-B694-340D80537561Q36240649-DCED6367-E33B-41A7-B87E-E3D18FC1B251Q36525986-5A2DBC3A-E9C1-4524-B78B-BA2D31ECEA5FQ36611216-A9E79B57-0650-4F73-8984-832CA0DFF4F3Q36656285-697BCF58-BFF8-4813-9AAF-52210607E009Q36811249-4A3E65D0-7E04-4A8C-A995-0E7CD2F16C16Q37020255-B0681F3A-24C0-494D-9644-8B612C0A64B9Q37062207-32586F3C-EDED-4C26-ACC9-89E38845CDA2Q37071435-03AA1DF3-FBC6-4216-AA50-DEA62FC512FCQ37245203-CDAB9194-BFF4-4B01-900B-FEB08938491FQ37247625-233E28B9-AD40-4A34-AF67-9AFC8CBA4103Q37396569-6C639A05-AD6B-4D8B-A9B9-EA158F77C9D7
P2860
Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission.
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Decay of K103N mutants in cell ...... her-to-child HIV transmission.
@ast
Decay of K103N mutants in cell ...... her-to-child HIV transmission.
@en
type
label
Decay of K103N mutants in cell ...... her-to-child HIV transmission.
@ast
Decay of K103N mutants in cell ...... her-to-child HIV transmission.
@en
prefLabel
Decay of K103N mutants in cell ...... her-to-child HIV transmission.
@ast
Decay of K103N mutants in cell ...... her-to-child HIV transmission.
@en
P2860
P50
P1433
P1476
Decay of K103N mutants in cell ...... her-to-child HIV transmission.
@en
P2093
Gayle Sherman
Shayne Loubser
P2860
P304
P356
10.1097/01.AIDS.0000222071.60620.1D
P407
P577
2006-04-01T00:00:00Z